R R

What Is Risdiplam?

Risdiplam is a prescription medication marketed under the brand name Evrysdi. It is a survival motor neuron 2, or SMN2, splicing modifier used to treat spinal muscular atrophy in children and adults. Spinal muscular atrophy is a genetic neuromuscular disease that damages motor neurons responsible for controlling voluntary muscle movement. Risdiplam is available as an oral solution and a 5 mg tablet for eligible patients. It is taken once daily and works by increasing production of functional survival motor neuron protein. Evrysdi is approved for patients of all ages, including infants younger than two months, using age-specific dosing.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Risdiplam?

Risdiplam is a prescription medication marketed under the brand name Evrysdi. It is a survival motor neuron 2, or SMN2, splicing modifier used to treat spinal muscular atrophy in children and adults. Spinal muscular atrophy is a genetic neuromuscular disease that damages motor neurons responsible for controlling voluntary muscle movement. Risdiplam is available as an oral solution and a 5 mg tablet for eligible patients. It is taken once daily and works by increasing production of functional survival motor neuron protein. Evrysdi is approved for patients of all ages, including infants younger than two months, using age-specific dosing.

read more about risdiplam ...

Copy this HTML:

Copy HTML Copied!

How Does Risdiplam Work?

Risdiplam changes how messenger RNA from the SMN2 gene is processed. Most patients with spinal muscular atrophy have missing or defective SMN1 genes, resulting in inadequate survival motor neuron protein production. The related SMN2 gene can produce some functional protein, but much of its RNA is normally processed in a way that limits production. Risdiplam promotes inclusion of exon 7 during SMN2 RNA splicing, increasing production of full-length survival motor neuron protein. Higher protein levels can support motor neuron function and improve or preserve certain motor abilities. Risdiplam does not correct the underlying SMN1 genetic defect.

What Condition Does Risdiplam Treat?

Risdiplam is FDA-approved for spinal muscular atrophy in pediatric and adult patients. SMA causes progressive weakness and muscle atrophy due to loss of motor neurons in the spinal cord and brainstem. Symptoms and severity vary according to disease type, age of onset, and other genetic factors. Early treatment may help preserve motor function before extensive motor neuron damage develops. Risdiplam can be considered for patients across different ages and SMA presentations, including very young infants. A neuromuscular specialist confirms the diagnosis, reviews previous therapies, and assesses swallowing, breathing, and motor function when developing the treatment plan.

How Should Risdiplam Be Taken?

Risdiplam is taken once daily, with or without food, and dosing depends on age and body weight. Infants younger than two months receive 0.15 mg/kg daily, while children aged two months to younger than two years receive 0.2 mg/kg daily. Patients aged two years and older weighing less than 20 kg receive 0.25 mg/kg daily. Patients aged two years and older weighing at least 20 kg receive 5 mg daily. The oral solution contains 0.75 mg/mL after preparation by a healthcare professional. Eligible patients may use the 5 mg tablet, which can be swallowed whole or dispersed in nonchlorinated drinking water according to the instructions. Doses should be measured or prepared using the specified equipment.

What Are the Side Effects and Warnings of Risdiplam?

Common adverse effects include fever, diarrhea, rash, mouth ulcers, and headache, although reported reactions vary by age and disease presentation. Respiratory infections and other complications may also occur in patients with spinal muscular atrophy. Animal studies identified potential embryo-fetal toxicity and adverse effects on male reproductive tissues, creating important reproductive precautions. Patients who can become pregnant should use effective contraception during treatment and for at least one month after the final dose. Men with reproductive potential should discuss possible fertility effects with their clinician. Patients should report persistent rash, unusual gastrointestinal symptoms, or significant changes in their neurological or respiratory condition.

Common Questions About Risdiplam

Is risdiplam the same as Evrysdi?

Yes. Evrysdi is the brand name for risdiplam, an SMN2 splicing modifier used to treat spinal muscular atrophy.

Can newborn babies receive risdiplam?

Yes. Evrysdi is approved for patients of all ages, including infants younger than two months, with age-based and weight-based dosing.

Is risdiplam available as a tablet?

Yes. Evrysdi is available as a 5 mg tablet for eligible patients and as an oral solution for patients who require weight-based liquid dosing.

Does risdiplam cure spinal muscular atrophy?

No. Risdiplam increases production of functional survival motor neuron protein but does not repair the underlying SMN1 gene defect or permanently cure SMA.

References

DailyMed - EVRYSDI (risdiplam) oral solution and tablets. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eceb9a99-7191-4be5-87c3-0102707cf98e. Date Accessed November 3, 2026.

Evrysdi. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi. Date Accessed November 3, 2026.

Risdiplam. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK608063/. Date Accessed November 3, 2026.

Risdiplam. MedlinePlus. https://medlineplus.gov/druginfo/meds/a625064.html. Date Accessed November 3, 2026.

Risdiplam Drug Label Information. U.S. Food and Drug Administration. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/394903. Date Accessed November 3, 2026.